🟢 Absci is trading 16.6% up today after encouraging ABS-201 safety data

Absci is trading at $9.38, up 16.60%, after interim Phase I/II data for ABS-201 showed no serious adverse events.

• September 16 Morgan Stanley conference commentary highlighted ABS-201, its AI-designed hair-loss drug.
• Data from 32 volunteers showed an estimated half-life of at least 65 days.
• The move is substantial relative to recent closes and appears primarily company-driven, though biotechnology strength, risk-on markets, and unavailable volume may also matter.